Flags in the Ground: SGO26 and the Danger of Competitive Urgency
The Society of Gynecologic Oncology’s 2024 meeting in San Juan showcased a wave of early‑stage data on ovarian and endometrial cancers. While press releases painted an optimistic picture, a deeper dive reveals modest response rates and limited patient cohorts. The blog warns that the rush to claim breakthroughs may mask critical gaps in trial design and endpoint clarity. Investors and clinicians are urged to scrutinize the raw data before drawing conclusions.
Bispecific ADCs and the Conditions Nobody Is Talking About
Sidewinder Therapeutics announced a $137 million Series B round to push precision bispecific antibody‑drug conjugates (BspADCs) into clinical trials. The funding follows a prior preview of the emerging bispecific ADC niche at AACR, highlighting a surge of early‑stage programs. While the concept...
AACR26 Off the Beaten Track
The article likens the AACR26 conference to the hidden trail leading to Old Harry rocks, emphasizing that the most valuable sessions are often tucked away from the main program. While headline talks dominate the schedule, lesser‑known sessions feature cutting‑edge data...
What Didn’t Exist Three Years Ago
The American Association for Cancer Research (AACR) annual meeting highlighted the latest direction of early‑stage drug development. This year’s sessions featured two prostate‑cancer candidates using mechanisms that were not in the clinic just eighteen months ago. The preview spotlights a...
What if Deleting the Oncogenic Protein Is the Wrong Move?
The article questions the prevailing belief that fully degrading oncogenic proteins outperforms merely inhibiting them. While inhibition has become a cornerstone of targeted cancer therapy, the piece argues that outright removal can trigger unforeseen biological responses. It highlights that protein...
Renal Cell Carcinoma Strategic Intelligence Report
The latest ASCO GU strategic intelligence report spotlights renal cell carcinoma (RCC) as a field entering a transformative phase. Analysts highlight emerging biomarkers, novel HIF‑2α inhibitors, and evolving immunotherapy combinations as potential high‑impact developments. While these advances promise to reshape...
Seven Ways to Skin KRAS: Emerging Approaches to Watch Out For
The article surveys seven early‑stage programmes tackling KRAS, each proposing a distinct therapeutic angle. While many firms still chase the classic model of deeper, longer, or more selective pathway blockade, these initiatives span elegant biochemical tricks to counterintuitive concepts that...
Strategic Intelligence Report on Bladder Cancer
At the recent ASCO‑GU meeting, industry leaders highlighted that the greatest threat to emerging bladder‑cancer programs is strategic, not clinical. Phase‑2 candidates are poised to enter Phase‑3 trials, but shifting control arms, evolving endpoints, and changing patient demographics risk rendering...
GU26 Prostate Cancer Strategic Intelligence Report
Following strong interest in the ASH25 hematologic malignancy intelligence report, Biotech Strategy Blog released a new strategic intelligence series covering the ASCO GU meeting data on prostate, bladder, and renal cell cancers. The first installment focuses on advanced prostate cancer,...
A Tale of Three Bispecific Cities
Three bispecific antibodies targeting PD‑1 and CTLA‑4—lorigerlimab, volrustomig, and cadonilimab—illustrate divergent engineering strategies. Lorig erlimab relies on a knob‑into‑hole heterodimer, volrustomig adopts a common light chain format, and cadonilimab incorporates Fc‑silencing mutations. Their distinct designs have produced markedly different safety...
Emerging Key Trends in Hematologic Malignancies
The article argues that the next wave of hematologic‑malignancy therapies will be shaped by early‑stage signals emerging from conference hallways rather than headline‑grabbing late‑phase trial data. It identifies five nascent trends—advanced immunotherapies, precision genomics, micro‑environment targeting, novel biomarker platforms, and...
How to Achieve Superior BCMA Response Rates without the Liability of Delayed MNTs
Recent analyses of BCMA CAR‑T therapies reveal that superior response rates can be achieved without the historically accepted trade‑off of delayed movement and neurocognitive toxicities (MNTs). Emerging data pinpoint specific construct features—particularly signaling domains and hinge designs—as the primary drivers...
The Payload Paradox: Why the Obsession with Potency May Be Holding the ADC Field Back
A European biotech is challenging the ADC status quo by prioritising novel targets and payloads over sheer potency. In an interview, the company’s CSO argues that the industry’s obsession with ultra‑potent cytotoxins like MMAE and DM1 is stalling progress, creating...
After T-DXd: Target, Payload, or Something Else?
The article examines the split debate over trastuzumab deruxtecan (T‑DXd) resistance, questioning whether the drug’s payload has failed or the tumor has lost HER2 engagement. Both mechanisms are supported by data, and the true challenge lies in identifying which drives...
Discombobulation on the KRAS Front
The KRAS field, once thought to be entering an execution phase after early successes, now faces unexpected data patterns across programs. Responses to KRAS inhibitors are behaving oddly, with transient dependencies and adaptive tumor rewiring emerging under therapeutic pressure. These...
There Are No Silver Bullets in China
Oncology innovation in China is shifting from fast‑follow biosimilars to globally competitive, next‑generation modalities, as revealed at the recent JP Morgan Healthcare conference. The momentum is driven primarily by emerging biotech firms in East Asia rather than the region’s traditional Big‑3...
The Wild Card in the G12D Space
The KRAS G12D inhibitor market is heating up as Jiangsu Hengrui, Revolution Medicines and Genfleet announce early‑stage programs, joining Astellas, which first entered the clinic with a KRAS G12D degrader. A new Chinese biotech has released preliminary clinical data, claiming...
A Trade-Off Coming Back to Haunt Bispecific Antibody Development
Bispecific antibody programs are increasingly confronting early platform decisions that were once deemed interchangeable. Choices made to simplify development or streamline regulatory pathways have embedded mechanistic assumptions that now limit efficacy ceilings and differentiation. As multiple immuno‑oncology bispecifics converge on...
Is AstraZeneca’s Surovatamig Underappreciated?
AstraZeneca’s head of Oncology Commercial labeled its early‑stage candidate surovatamig ‘underappreciated’ during the J.P. Morgan Healthcare conference, prompting analysts to reassess the drug’s market potential. The comment followed the presentation of phase 1 data at the American Society of Hematology meeting, where...
When the Boat Matters More than You Think
Two biotech firms announced phase‑3 oncology trials in San Francisco, enrolling fewer than 20 and fewer than 50 patients respectively. The ultra‑small cohorts reflect a growing trend to accelerate drug development for rare cancers, leveraging expedited regulatory pathways. While the approach...
A Bear’s Eye View of the Zanidatamab Data in Gastric Cancer
Jazz Pharmaceuticals presented zanidatamab data from the HERIZON‑GEA‑01 phase 3 trial at the ASCO GI Symposium, targeting HER2‑positive gastric cancer. The company touted the results as practice‑changing, prompting sell‑side analysts to echo the optimism. However, the stock fell 4‑5% as investors...